

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

INSIDE INFORMATION POTENTIAL TRANSACTION

This announcement is made by Essex Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors of the Company (the “**Board**”) would like to inform the shareholders of the Company (the “**Shareholders**”) that the Group is in discussion with an independent third party in relation to the potential co-development of a biopharmaceutical ophthalmic product and the licensing of the relevant intellectual property rights thereof (the “**Potential Transaction**”). As at the date of this announcement, no legally binding agreement has been entered into by the relevant parties. The Potential Transaction, if materialised, may constitute discloseable transaction(s) of the Company under the Listing Rules, and the Company will comply with the relevant requirements of the Listing Rules if and when necessary.

The Board has also noted the recent unusual price movement and increases in trading volume of the shares of the Company (the “**Shares**”). Having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirms that, save as the Potential Transaction, it is not aware of any reason for such price or volume movements or of any information which must be announced to avoid a false market in the Shares or of any inside information that needs to be disclosed under Part XIVA of the SFO.

The Potential Transaction may or may not materialise. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 30 September 2020

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.